South Korea · Delayed Price · Currency is KRW BioNote Statistics
Total Valuation
BioNote has a market cap or net worth of KRW 564.58 billion. The enterprise value is 218.11 billion.
| Market Cap | 564.58B |
| Enterprise Value | 218.11B |
Important Dates
The last earnings date was Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNote has 101.36 million shares outstanding. The number of shares has decreased by -0.78% in one year.
| Current Share Class | 101.36M |
| Shares Outstanding | 101.36M |
| Shares Change (YoY) | -0.78% |
| Shares Change (QoQ) | -0.19% |
| Owned by Insiders (%) | 58.37% |
| Owned by Institutions (%) | 0.20% |
| Float | 14.27M |
Valuation Ratios
The trailing PE ratio is 4.80.
| PE Ratio | 4.80 |
| Forward PE | n/a |
| PS Ratio | 4.91 |
| PB Ratio | 0.33 |
| P/TBV Ratio | 0.33 |
| P/FCF Ratio | 27.33 |
| P/OCF Ratio | 17.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 1.62, with an EV/FCF ratio of 10.56.
| EV / Earnings | 1.85 |
| EV / Sales | 1.90 |
| EV / EBITDA | 1.62 |
| EV / EBIT | 1.74 |
| EV / FCF | 10.56 |
Financial Position
The company has a current ratio of 35.92, with a Debt / Equity ratio of 0.00.
| Current Ratio | 35.92 |
| Quick Ratio | 33.06 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.13 |
| Debt / FCF | 0.17 |
| Interest Coverage | 61.31 |
Financial Efficiency
Return on equity (ROE) is 7.15% and return on invested capital (ROIC) is 0.70%.
| Return on Equity (ROE) | 7.15% |
| Return on Assets (ROA) | 0.68% |
| Return on Invested Capital (ROIC) | 0.70% |
| Return on Capital Employed (ROCE) | 1.06% |
| Revenue Per Employee | 386.22M |
| Profits Per Employee | 394.80M |
| Employee Count | 298 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 1.95 |
Taxes
In the past 12 months, BioNote has paid 15.75 billion in taxes.
| Income Tax | 15.75B |
| Effective Tax Rate | 11.81% |
Stock Price Statistics
The stock price has increased by +18.28% in the last 52 weeks. The beta is 0.98, so BioNote's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +18.28% |
| 50-Day Moving Average | 5,720.80 |
| 200-Day Moving Average | 5,183.18 |
| Relative Strength Index (RSI) | 48.70 |
| Average Volume (20 Days) | 55,689 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioNote had revenue of KRW 115.09 billion and earned 117.65 billion in profits. Earnings per share was 1,160.96.
| Revenue | 115.09B |
| Gross Profit | 63.98B |
| Operating Income | 18.39B |
| Pretax Income | 133.40B |
| Net Income | 117.65B |
| EBITDA | 27.24B |
| EBIT | 18.39B |
| Earnings Per Share (EPS) | 1,160.96 |
Balance Sheet
The company has 349.96 billion in cash and 3.49 billion in debt, giving a net cash position of 346.48 billion or 3,418.23 per share.
| Cash & Cash Equivalents | 349.96B |
| Total Debt | 3.49B |
| Net Cash | 346.48B |
| Net Cash Per Share | 3,418.23 |
| Equity (Book Value) | 1.70T |
| Book Value Per Share | 16,891.14 |
| Working Capital | 407.29B |
Cash Flow
In the last 12 months, operating cash flow was 31.61 billion and capital expenditures -10.94 billion, giving a free cash flow of 20.66 billion.
| Operating Cash Flow | 31.61B |
| Capital Expenditures | -10.94B |
| Free Cash Flow | 20.66B |
| FCF Per Share | 203.84 |
Margins
Gross margin is 55.59%, with operating and profit margins of 15.98% and 102.22%.
| Gross Margin | 55.59% |
| Operating Margin | 15.98% |
| Pretax Margin | 115.90% |
| Profit Margin | 102.22% |
| EBITDA Margin | 23.67% |
| EBIT Margin | 15.98% |
| FCF Margin | 17.95% |
Dividends & Yields
This stock pays an annual dividend of 200.00, which amounts to a dividend yield of 3.64%.
| Dividend Per Share | 200.00 |
| Dividend Yield | 3.64% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 17.23% |
| Buyback Yield | 0.78% |
| Shareholder Yield | 4.41% |
| Earnings Yield | 20.84% |
| FCF Yield | 3.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNote has an Altman Z-Score of 7.59 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.59 |
| Piotroski F-Score | 6 |